mTOR Inhibitor

Japanese Journal of Cancer and Chemotherapy

Volumn 38, Issue 1, 2011, Pages 7-11

  Muro, Kei ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Everolimus; PI3K AKT mTOR pathway; Rapamycin; Temsirolimus

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; S6 KINASE; TUMOR MARKER;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION; DRUG EFFICACY; DRUG TARGETING; KIDNEY CARCINOMA; MICROVASCULAR ENDOTHELIAL CELL; PANCREAS TUMOR; PANCREATIC NEUROENDOCRINE TUMOR; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSLATION REGULATION;

EID: 79957558949     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Courtney KD, Corcoran RB and Engelman JA: The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-1083, 2010.
2. Loewith R, Jacintoe, Wullschleger S, et al: Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10: 457-468, 2002. (Pubitemid 35284167)
3. Sarbassov DD, Guertin DA, Ali SM, et al: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101, 2005. (Pubitemid 40262113)
4. Hudes G, Carducci M, Tomczak P, et al: Temesirorimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356: 2271-2281, 2007. (Pubitemid 46849157)
5. Motzer RJ, Escudier B, Oudard S, et al: Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-456, 2008.
6. Doi T, Muro K, Boku N, et al: Multicenter phase II study of everolimus in patients with previously treated gastric cancer. J Clin Oncol 28: 1904-1910, 2010.
7. Yu K, Toral-Barza L. Discafani C, et al: mTOR, a novel target in breast cancer; the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8: 249-258, 2001. (Pubitemid 32947647)
8. Galanis E, Buckner JC, Maurer MJ, et al: Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A North Central Cancer Treatment Group Study. J Clin Oncol 23: 5294-5304, 2005. (Pubitemid 46206983)